Dickerson Jaime E, Harvey Alison E, Brown Reay H
Sight Sciences, Inc., Menlo Park, CA, USA.
North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
Clin Ophthalmol. 2024 May 23;18:1433-1440. doi: 10.2147/OPTH.S464233. eCollection 2024.
To determine if there was an association between severity of glaucoma and intraocular pressure (IOP) and medication (med) outcomes for patients in the ROMEO (etrospective, bservational, ulticenter valuation of MNI) study.
Eleven ophthalmology practices in 8 US states.
Post-hoc analysis of all eyes enrolled and treated with ab interno canaloplasty and trabeculotomy in the retrospective, multicenter ROMEO study.
Eyes were grouped according to visual field mean deviation (MD): mild (MD better than -6 dB), moderate (MD between -6 and -12 dB), advanced (-12 dB or worse). IOP and med outcomes at 12 months were compared across groups. Least squares regression was used to assess the relationship of MD with month 12 IOP. Outcomes for 1 and last MD deciles were compared as a sensitivity analysis.
One hundred and twenty-seven eyes were available for analysis including 79 mild, 42 moderate, 6 advanced. Most eyes had a reduction in IOP at Month 12 (70%) with most at 18 mmHg or less. Percentage IOP reduction was similar across the groups (mild 16.9%, moderate 18.6%, advanced 18.0%) with mean month 12 IOP between 14 and 16 mmHg. Medications were also reduced in all three groups; -0.8 (mild, P < 0.001), -0.55 (moderate, P < 0.05), and -1.0 (advanced, P = 0.139, ns). Regression analysis revealed no relationship between month 12 IOP and MD. Med reductions were observed for all groups with a reduction of 1 or more medications seen in (%, 95% CI) 69%, 59-79 (mild), 50%, 35-65 (moderate), and 60%, 21-99 (advanced). Secondary interventions tended to have greater incidence with worse MD likely reflecting lower desired IOP targets.
Analysis of data from the ROMEO study suggests that similar meaningful IOP and med reductions can be expected across the range of disease severity studied.
在ROMEO(MNI的回顾性、观察性、多中心评估)研究中,确定青光眼严重程度与眼压(IOP)及药物治疗效果之间是否存在关联。
美国8个州的11家眼科诊所。
在回顾性多中心ROMEO研究中,对所有接受内路小梁切开术和小梁成形术的眼睛进行事后分析。
根据视野平均偏差(MD)对眼睛进行分组:轻度(MD优于-6 dB)、中度(MD在-6至-12 dB之间)、重度(-12 dB或更差)。比较各组在12个月时的眼压和药物治疗效果。采用最小二乘法回归分析评估MD与第12个月眼压之间的关系。作为敏感性分析,比较了第1和最后一个MD十分位数的治疗效果。
共有127只眼睛可供分析,其中轻度79只、中度42只、重度6只。大多数眼睛在第12个月时眼压降低(70%),大多数降低至18 mmHg或更低。各组眼压降低百分比相似(轻度16.9%,中度18.6%,重度18.0%),第12个月时平均眼压在14至16 mmHg之间。三组的药物使用量也都有所减少;分别为-0.8(轻度,P<0.001)、-0.55(中度,P<0.05)和-1.0(重度,P = 0.139,但无统计学意义)。回归分析显示第12个月眼压与MD之间无关联。所有组均观察到药物使用量减少,减少1种或更多药物的比例(%,95%置信区间)分别为:69%,59 - 79(轻度)、50%,35 - 65(中度)和60%,21 - 99(重度)。随着MD变差,二次干预的发生率往往更高,这可能反映了更低的目标眼压。
对ROMEO研究数据的分析表明,在所研究的疾病严重程度范围内,预期眼压和药物使用量会有相似且有意义的降低。